The $38 million Targeted Translation Research Accelerator (TTRA) initiative is a four-year funding opportunity of the Medical Research Future Fund, aimed at improving the prevention, diagnosis, management and treatment of diabetes, cardiovascular disease and their related complications in Australia.

The $38 million Targeted Translation Research Accelerator (TTRA) initiative is a four-year funding opportunity of the Medical Research Future Fund, aimed at improving the prevention, diagnosis, management and treatment of diabetes, cardiovascular disease and their related complications in Australia.

The program is delivered by MTPConnect in Partnership with ANDHealth, the Medical Device Partnering Program (MDPP) and UniQuest. As a venture partner, ANDHealth will provide mentoring and commercialisation advice to digital health applicants, and funding recipients, helping them reach commercial proof-of-concept.

The TTRA program will support eligible organisations seeking $200,000 - $750,000 for up to 24 months, who also provide an in-kind contribution to the value of 50% of the funding requested, to develop innovative preventative, diagnostic, therapeutic and disease management products/solutions for identified priorities associated with diabetes and cardiovascular disease. Expressions of interest are now open.

Submissions for the first round of Research Projects funding close on 22 February 2021.

Learn More